Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary marketplace / Explore private companies / Adaptive Biotechnologies IPO
Adaptive Biotechnologies

Adaptive Biotechnologies IPO

$1.35B
Series F-1 Valuation, Jan 2018
Register for details
For more details on financing and valuation of private companies similar to Adaptive Biotechnologies before its IPO, register or log in today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Adaptive Biotechnologies IPO date and status

2009
Founded
Jun 2019
IPO Completed

Company details

Adaptive Biotechnologies is a biotechnology company specializing immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems.
Founded
2009
Headquarters
Seattle, WA, United States
Forge Price 1
Price not available
Market Activity 2
Limited
Last Matched Price
Post-Money Valuation 3
$1.35B
Total Funding
$561.37MM
Last Funding Round
Series F-1

Learn more about Adaptive Biotechnologies

To invest in Adaptive Biotechnologies pre-IPO

Can you invest in Adaptive Biotechnologies pre-IPO?

You may invest in Adaptive Biotechnologies as it is a public company listed on the NASDAQ with ticker ADPT. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Adaptive Biotechnologies before it goes public?

You can no longer sell shares of Adaptive Biotechnologies on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Adaptive Biotechnologies shares?

Forge can no longer determine the value of Adaptive Biotechnologies shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Adaptive Biotechnologies a publicly traded company?

Adaptive Biotechnologies became a public company following its IPO on 06/27/2019 and is now traded on the NASDAQ under the ticker ADPT.

To learn more about Adaptive Biotechnologies potential IPO

Will Adaptive Biotechnologies go IPO?

Adaptive Biotechnologies became a public company following its IPO on 06/27/2019 and is now traded on the NASDAQ under the ticker ADPT.

What is Adaptive Biotechnologies’ IPO price?

The IPO price of Adaptive Biotechnologies is not currently available.

When was Adaptive Biotechnologies founded?

Adaptive Biotechnologies was founded in 2009.

What is Adaptive Biotechnologies funding to date?

Adaptive Biotechnologies has raised $561.37MM to date.

Adaptive Biotechnologies pre-IPO valuation and funding rounds

Funding history chart
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
01/04/2018 Series F-1 $45MM $10.67 $1.35B Microsoft
Price per Share
$ xx.xx
Shares Outstanding
4,217,985
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Microsoft
05/06/2015 Series F $195.1MM $8.97 $1.08B Alexandria Real Estate Equities, Bd Biosciences, Casdin Capital, Celgene, Foresite Capital Management, Illumina, Laboratory Corporation Of America, Matrix Capital Management, Rock Springs Capital, Senator Investment Group, Tiger Global Management, Viking Global Investors
Price per Share
$ xx.xx
Shares Outstanding
21,761,676
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Real Estate Equities, Bd Biosciences, Casdin Capital, Celgene, Foresite Capital Management, Illumina, Laboratory Corporation Of America, Matrix Capital Management, Rock Springs Capital, Senator Investment Group, Tiger Global Management, Viking Global Investors
01/22/2015 Series E1 $105.12MM $6.04 $652.13MM Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
17,407,441
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
01/21/2015 Series E $93.75MM $6.04 $321.37MM Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
15,524,350
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
07/29/2014 Series D $107MM $5.55 $261.89MM Viking Global Investors
Price per Share
$ xx.xx
Shares Outstanding
19,269,117
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Viking Global Investors
07/09/2013 Series C $5.02MM $2.64 $76.08MM Ares Capital, Viking Global Investors
Price per Share
$ xx.xx
Shares Outstanding
1,905,206
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ares Capital, Viking Global Investors
06/02/2011 Series B $5.82MM $1.71 $49.04MM Angel Investors
Price per Share
$ xx.xx
Shares Outstanding
3,399,033
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Angel Investors
03/24/2010 Series A $4.55MM $1.00 $27.52MM Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
4,550,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Adaptive Biotechnologies IPO news and media highlights

Adaptive Biotechnologies Revenues Rise 26 Percent in Q4, 57 Percent in 2021

Fourth quarter sequencing revenue increased 81 percent to $23.1 million year over year, while development revenue dropped 15 percent to $14.9 million.

Adaptive Biotechnologies and Microsoft Partner To Decode COVID-19 Immune Response and Provide Open Data Access

Adaptive Biotechnologies and Microsoft Partner To Decode COVID-19 Immune Response and Provide Open Data Access
Browse More Insights

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
Spyglass PharmaSpyglass PharmaNot available$ xx.xxSeries D$350.04MM$2.33$75MM
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61MM$1.62$40MM
OriginOriginNot available$ xx.xxNot available------

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Actively traded

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
SpaceX SpaceX $550.00 +$102.77 (22.98%)High $xxx.xx
Anduril Anduril $114.78 +$9.78 (9.31%)High $xxx.xx
Databricks Databricks $197.72 +$0.06 (0.03%)High $xxx.xx

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
Anduril Anduril $114.78 +$9.78 (9.31%)High $xxx.xx
Databricks Databricks $197.72 +$0.06 (0.03%)High $xxx.xx
Groq Groq $29.77 -$0.01 (0.03%)High $xxx.xx

Forge, your trusted partner for pre-IPO insights and Adaptive Biotechnologies data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Jul 16, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.